Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes : Randomized controlled study

Oita, Mayuko; Miyoshi, Hideaki; Ono, Kota et al.

Endocrine Journal, 2018, 65(2), 141-150

Permalink : https://hdl.handle.net/2115/68416

このアイテムのアクセス数:948件（2026-08-18 13:46 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
65_EJ17-0303 pdf 822 KB 529

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/68416
タイトル
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes : Randomized controlled study
著者
Oita, Mayuko ; Miyoshi, Hideaki ; Ono, Kota ; Nakamura, Akinobu ; Cho, Kyu Yong ; Nomoto, Hiroshi ; Yamamoto, Kohei ; Omori, Kazuno ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya
著者名
Oita, Mayuko
e-Rad_Researcher
30360902
著者名
Miyoshi, Hideaki
著者名
Ono, Kota
e-Rad_Researcher
70552420
著者名
Nakamura, Akinobu
著者名
Cho, Kyu Yong
著者名
Nomoto, Hiroshi
著者名
Yamamoto, Kohei
著者名
Omori, Kazuno
著者名
Manda, Naoki
著者名
Kurihara, Yoshio
著者名
Aoki, Shin
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
言語
英語
キーワード
Satisfaction
Quality of life
Trelagliptin
Type 2 diabetes
発行日
2018-02
出版者
The Japan Endocrine Society
収録物名
Endocrine Journal
巻(号)
65(2)
ページ
141-150
抄録
We compared treatment satisfaction between daily dipeptidyl peptidase-4 (DPP-4) inhibitors and a weekly DPP-4 inhibitor in patients with type 2 diabetes. The study was a 12-week, open-label, randomized, multicenter, controlled trial. Participants were Japanese patients with type 2 diabetes who had received daily DPP-4 inhibitors for more than 3 months. Patients were randomly assigned to a treatment cohort: (1) a group that continued taking daily DPP-4 inhibitors (daily group); or (2) a group that switched from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin (weekly group). The primary outcome was the change in treatment satisfaction levels from baseline to 12 weeks between the two groups, according to Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Diabetes Therapy-Related Quality of Life (DTR-QOL) questionnaire scores. The changes in glycemic control and body weight were also assessed. Of 49 patients initially enrolled in the study, 47 completed the study. The change in DTSQ scores in the weekly group was not significantly different from that in the daily group. However, the improvements in total score and subscale domains 1 and 2 in the DTR-QOL analysis, which relate to burden on social/daily activities and anxiety/dissatisfaction with treatment, were significantly greater in the weekly group than the daily group (p = 0.048, 0.013 and 0.045, respectively). Mean changes in glycated hemoglobin levels and body weight were comparable between the groups. Switching from daily DPP-4 inhibitors to a weekly DPP-4 inhibitor, trelagliptin, could partially improve treatment satisfaction levels in patients with type 2 diabetes without affecting glycemic control.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
0918-8959
関連情報
PMID
29093280
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1507/endocrj.EJ17-0303